bioMerieux (OTCMKTS:BMXMF) Trading Down 2.3% - What's Next?

Key Points

• bioMerieux's stock price dropped 2.3% to $145.64, following increased trading volume of 1,504 shares, significantly higher than the average of 10 shares.
• Royal Bank of Canada downgraded the stock from a "moderate buy" to a "hold" rating, which may impact investor sentiment.
• bioMerieux specializes in in vitro diagnostic solutions for infectious diseases, operating in various global markets including the Americas, Europe, and Asia Pacific.

Shares of bioMerieux (OTCMKTS:BMXMF - Get Free Report) were down 2.3% on Tuesday . The company traded as low as $145.64 and last traded at $145.64. Approximately 1,504 shares changed hands during mid-day trading, an increase of 14,865% from the average daily volume of 10 shares. The stock had previously closed at $149.14.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada downgraded bioMerieux from a "moderate buy" rating to a "hold" rating in a research report on Wednesday, May 7th.

bioMerieux Price Performance

The company has a debt-to-equity ratio of 0.08, a current ratio of 2.20 and a quick ratio of 1.29. The firm has a 50-day moving average price of $142.63 and a 200 day moving average price of $131.68.

bioMerieux Company Profile

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.